Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2021 | Improving the efficacy of immunotherapy using anti-angiogenic agents in GI malignancies

Hans Prenen • 22 Jan 2021
ASCO GI 2021
Gastrointestinal Cancer Liver Cancer Antibodies Lenvatinib
LEAP-005

Hans Prenen, MD, PhD, UZ Leuven, Leuven, Belgium, discusses key data presented at this years American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, including the combined use of anti-angiogenic factors with immunotherapy as evaluated in the LEAP-005 study (NCT03797326) which combined a checkpoint inhibitor with lenvatinib. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Hans Prenen

1:52
Patient-derived organoids as models for chemoradiation response prediction in GI malignancies
Hans Prenen • 22 Jan 2021
1:58
DPYD deficiency in patients with severe toxicity after 5-fluorouracil
Hans Prenen • 22 Jan 2021
2:26
alloSHRINK: Phase I first-in-human study evaluating CYAD-101, an allogeneic CAR-T in mCRC
Hans Prenen • 22 Jan 2021

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals